Guizhou Yibai Pharmaceutical (600594.SH): Compound Cantharidin Capsules and others are expected to be selected for centralized procurement.

Guizhou Yibai Pharmaceutical (600594.SH) announced that the company recently participated in the bidding for the national traditional Chinese medicine procurement alliance centralized procurement (second batch continuation). According to the notice released by the National Traditional Chinese Medicine Joint Procurement Office regarding the "Announcement of the Supply List for Selected Varieties in the National Traditional Chinese Medicine Procurement Alliance Centralized Procurement," the company's products, Compound Venenum Bufonis Capsules and Ginkgo Biloba Injection, have been selected in this continuation procurement. During the procurement period, medical institutions will prioritize the use of the selected drugs from this continuation procurement and ensure the completion of the agreed procurement volume. If the company subsequently signs procurement contracts and implements them, it will facilitate further expansion of the sales scope of the selected products, increase the market share of those products, enhance the company's brand influence, and have a positive impact on the company's long-term development.